Hepatocellular carcinoma (HCC) still remains a global health challenge as it shows genetic heterogeneity and limited therapy response. In a new study, the cellular responses in HCC that accompany the nearly universal repression of urea cycle enzymes and consequent arginine auxotrophy were investigated, since previous findings demonstrated that that HCC consistently represses urea cycle gene expression and thus become auxotrophic for exogenous arginine becoming severe disease.

Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) has patented thiazolopyrimidones acting as discoidin domain-containing receptor 1 (DDR1) and/or DDR2 inhibitors reported to be useful for the treatment of atherosclerosis, cancer, cirrhosis, hepatic fibrosis, pulmonary fibrosis, lupus nephritis, osteoarthritis and rheumatoid arthritis, among others.

Ascentage Pharma has divulged spirocyclic indenes acting as GTPase KRAS (Gly12Cys mutant) inhibitors reported to be useful for the treatment of cancer.

Guangdong Newopp Biopharmaceuticals has disclosed Son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.

Jingrui Biopharma has described bromodomain and extra-terminal (BET) inhibitors, particularly bromodomain-containing protein 4 (BD1 domain) (Brd4 BD1) inhibitors, reported to be useful for the treatment of cancer.

Medshine Discovery has disclosed pyrazolopyrazine-linked tricyclic compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of cancer.

CGeneTech announced that the ALK inhibitor CGT-9475, which was independently developed by Shengshi Tyco, has been approved by the FDA to enter clinical trials aiming to evaluate the candidate's ability to overcome the issues of drug resistance and brain metastasis in the treatment of lung cancer.

Cullgen announced that the Chinese National Medical Products Administration (NMPA) has allowed the IND application for CG-001419, a first-in-class, selective, potent oral targeted protein tyrosine receptor kinase (TRK) degrader for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive cancers, which have been identified in numerous solid tumors including non-small cell lung, breast and pancreatic cancers.

Reata Pharmaceuticals has described ursolic acid derivatives acting as nitric oxide (NO) production inhibitors and/or nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) activators reported to be useful for the treatment of cancer and inflammatory disorders, among other disorders.

DexTech Medical announced that its application for a phase I clinical trial of OsteoDex in patients with multiple myeloma has been submitted to the Medical Products Agency on June 23, 2022 and it has been approved and granted permission August 10, 2022.